Ricardo Robles-Campos1,2, Roberto Brusadin3, Asunción López-Conesa3, Víctor López-López3, Álvaro Navarro-Barrios3, José J López-Espín4, Julio Arévalo-Pérez5, Pascual Parrilla3. 1. Department of Liver Surgery and Transplantation, Virgen de La Arrixaca Clinic, University Hospital, IMIB-Arrixaca, Murcia, Spain. rirocam@um.es. 2. Department of Surgery, Virgen de La Arrixaca Clinic, University Hospital, El Palmar, Murcia, Spain. rirocam@um.es. 3. Department of Liver Surgery and Transplantation, Virgen de La Arrixaca Clinic, University Hospital, IMIB-Arrixaca, Murcia, Spain. 4. Miguel Hernandez University, Elche, Alicante, Spain. 5. Radiology Department, Memorial Sloan Kettering Cancer Center, New York, USA.
Abstract
BACKGROUND: To compare the overall survival (OS) and disease-free survival (DFS) of Tourniquet-ALPPS (T-ALPPS) and conventional two-stage hepatectomy (TSH) in patients with colorectal liver metastases (CRLM). METHODS: A retrospective study from a prospectively collected database was performed between October 2000 and July 2016. TSH was performed before September 2011, after which time T-ALPPS became the technique of choice. A propensity score matching (PSM) was performed based on a 1:1 ratio with consideration of the following variables: number and size of metastases, bilobar disease presence, and chemotherapy received. RESULTS: Thirty-four patients received T-ALPPS; 41 patients received TSH. After PSM, 21 patients remained in each group, with 100% resectability in the T-ALPPS group and 90.5% resectability in the TSH group. The median OS for TSH was 41 months; for T-ALPPS, the median OS was 36 months (P = 0.925). The median DFS was 16 months in the TSH group; the median DFS was 9 months in the T-ALPPS group (P = 0.930). The 1-, 3-, and 5-year OS for TSH was 81%, 66.7%, and 23.8% vs. 76.2%, 57.1%, and 22.9% for T-ALPPS, respectively. The 1-, 3-, and 5-year DFS for TSH was 66.7%, 9.5%, and 5% vs. 44.6%, 11.1%, and 11.1% for T-ALPPS, respectively. The volume increase with T-ALPPS was superior to that with TSH (68% vs. 39%; P = 0.018). There were no differences in morbidity and mortality after stages 1 and 2. CONCLUSIONS: T-ALPPS produces a similar outcome to TSH, indicating that it could be a safe and effective alternative for curative hepatectomy for all patients.
BACKGROUND: To compare the overall survival (OS) and disease-free survival (DFS) of Tourniquet-ALPPS (T-ALPPS) and conventional two-stage hepatectomy (TSH) in patients with colorectal liver metastases (CRLM). METHODS: A retrospective study from a prospectively collected database was performed between October 2000 and July 2016. TSH was performed before September 2011, after which time T-ALPPS became the technique of choice. A propensity score matching (PSM) was performed based on a 1:1 ratio with consideration of the following variables: number and size of metastases, bilobar disease presence, and chemotherapy received. RESULTS: Thirty-four patients received T-ALPPS; 41 patients received TSH. After PSM, 21 patients remained in each group, with 100% resectability in the T-ALPPS group and 90.5% resectability in the TSH group. The median OS for TSH was 41 months; for T-ALPPS, the median OS was 36 months (P = 0.925). The median DFS was 16 months in the TSH group; the median DFS was 9 months in the T-ALPPS group (P = 0.930). The 1-, 3-, and 5-year OS for TSH was 81%, 66.7%, and 23.8% vs. 76.2%, 57.1%, and 22.9% for T-ALPPS, respectively. The 1-, 3-, and 5-year DFS for TSH was 66.7%, 9.5%, and 5% vs. 44.6%, 11.1%, and 11.1% for T-ALPPS, respectively. The volume increase with T-ALPPS was superior to that with TSH (68% vs. 39%; P = 0.018). There were no differences in morbidity and mortality after stages 1 and 2. CONCLUSIONS:T-ALPPS produces a similar outcome to TSH, indicating that it could be a safe and effective alternative for curative hepatectomy for all patients.
Authors: B I Røsok; T Høst-Brunsell; K W Brudvik; U Carling; E Dorenberg; B Björnsson; R A Lothe; B A Bjørnbeth; P Sandström Journal: HPB (Oxford) Date: 2019-02-11 Impact factor: 3.647
Authors: M Makuuchi; B L Thai; K Takayasu; T Takayama; T Kosuge; P Gunvén; S Yamazaki; H Hasegawa; H Ozaki Journal: Surgery Date: 1990-05 Impact factor: 3.982
Authors: Junichi Shindoh; Jean-Nicolas Vauthey; Giuzeppe Zimmitti; Steven A Curley; Steven Y Huang; Armeen Mahvash; Sanjay Gupta; Michael J Wallace; Thomas A Aloia Journal: J Am Coll Surg Date: 2013-04-28 Impact factor: 6.113
Authors: Erik Schadde; Dimitri Aristotle Raptis; Andreas A Schnitzbauer; Victoria Ardiles; Christoph Tschuor; Mickaël Lesurtel; Eddie K Abdalla; Roberto Hernandez-Alejandro; Elio Jovine; Marcel Machado; Massimo Malago; Ricardo Robles-Campos; Henrik Petrowsky; Eduardo De Santibanes; Pierre-Alain Clavien Journal: Ann Surg Date: 2015-11 Impact factor: 12.969
Authors: Per Sandström; Bård I Røsok; Ernesto Sparrelid; Peter N Larsen; Anna L Larsson; Gert Lindell; Nicolai A Schultz; Bjorn A Bjørnbeth; Bengt Isaksson; Magnus Rizell; Bergthor Björnsson Journal: Ann Surg Date: 2018-05 Impact factor: 12.969